MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
PMV Pharmaceuticals, Inc

PMVP

#3299
PMV Pharmaceuticals, Inc
1.70
+25.93%
Sector:
Base:
Profit Currency:
Daily Range
1.70
1.70
Year Range
0.81
1.84
Daily Change
+25.93%
Monthly Change
+38.21%
6 month change
+18.06%
Year Change
+21.43%
Previous Close
1.35
Open
1.70
Bid
Ask
Low
1.70
High
1.70
Volume
18
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. PMVP
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

News

Investing Investing
PMVP
2 days ago, 13:05
PMV Pharma’s rezatapopt study published in New England Journal
Investing Investing
PMVP
2025.10.27
OrbiMed Advisors sells PMV Pharma (PMVP) shares for $1.52 million
Seeking Alpha Seeking Alpha
PMVP
2025.10.25
PMV Pharmaceuticals, Inc. (PMVP) Presents at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Slideshow (NASDAQ:PMVP) 2025-10-25
Investing Investing
PMVP
2025.10.24
PMV Pharmaceuticals stock rises on positive cancer drug trial data
Investing Investing
PMVP
2025.10.13
PMV Pharma to present initial data on TP53 mutation therapy at cancer conference
Investing Investing
PMVP
2025.09.19
PMV Pharmaceuticals stock holds Buy rating at H.C. Wainwright on trial data
Seeking Alpha Seeking Alpha
PMVP
2025.09.11
PMV Pharmaceuticals, Inc. (PMVP) Special Call - Slideshow (NASDAQ:PMVP)
Investing Investing
PMVP
2025.09.10
PMV Pharmaceuticals stock rating reiterated at Buy by TD Cowen
Benzinga Benzinga
PMVP
2025.09.10
Why Is PMV Pharmaceuticals Stock Falling Wednesday - PMV Pharma (NASDAQ:PMVP)
Investing Investing
PMVP
2025.09.10
PMV Pharmaceuticals stock soars after promising cancer drug trial results
Investing Investing
PMVP
2025.09.10
PMV Pharma reports 33% response rate in TP53 Y220C mutation trial
Investing Investing
PMVP
2025.07.04
Ticktin Robert, general counsel, sells PMV Pharma shares for $24,651

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd